MGI REPORTS ANTICIPATED LOSSMGI Pharma Inc.(NASDAQ:MOGN) of Minneapolis reported anincrease in both its fourth-quarter and year-end revenues;nonetheless, the company reported net losses of $2 million forthe quarter and $6.5 million for the year. Dr. Kenneth Tempero,chairman and chief executive officer, said that "thecontributions made by our commercial operations weresufficient to cover all of our business expenditures except ouraggressive investment in product development." He said thecompany holds nearly $27 million in cash and short-terminvestments. During 1990, the company acquired its firstmarketable product, Didronel I.V., and advanced its two leadproducts, MGI 647 and MGI 136, into Phase III trials.

Fourth quarter ended Dec. 31.

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $1,595 1,157 +38Net income (loss) (2,115) (173) -1,112Net income per share (loss) (.26) (.03) -766Outstanding shares 8,226 8,186 neg.

Year ended Dec. 31.

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $6,364 4,780 +33Net income (loss) (6,429) 2,197 N/ANet income per share (loss) (.80) .24 N/AOutstanding shares 8,213 8,147 neg.

NORTH AMERICAN INCOME INCREASES

North American Biologicals Inc. (NASDAQ:NBIO) of MiamiPresident David J. Gury said: "Increased plasma shipmentscombined with moderately improved pricing contributed to ourincreased sales. Gross margins and operating income improvedsignificantly as a result of a better product mix, more stableproduction costs and ongoing containment measures."

Fourth quarter ended Dec. 31.

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $17,384 16,338 +6Net income (loss) 602 515 +14Net income per share (loss) .04 .03 +33Outstanding shares 15,609 15,421 +1

Year ended Dec. 31.

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $72,822 59,225 +23Net income (loss) 2,338 1,325 +76Net income per share (loss) .15 .09 +66Outstanding shares 15,566 15,440 +1

EPITOPE REPORTS DEEPER LOSS

Epitope Inc. (ASE:EPT) of Beaverton, Ore., President and ChiefExecutive Officer Adolph J. Ferro said the decrease in totalrevenues during the first quarter was due to the phasing out ofan unprofitable parentage testing business and fewer researchgrants.

First quarter ended Dec. 31.

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $815 $1,013 -19Net income (loss) (775) (541) -43Net income per share (loss) (.11) (.08) -38

(c) 1997 American Health Consultants. All rights reserved.